SCHEMBL3015207

SCHEMBL3015207

O=S(=O)(c1ccc(Br)cc1)C1CCN(c2nc(Cc3ccc(F)c(F)c3)cs2)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.36
RAB9A P51151 4/20 0.36
NPC1 O15118 3/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
CACNA1G O43497 2/20 0.35
CACNA1H O95180 2/20 0.35
CACNA1I Q9P0X4 2/20 0.35
HTR2A P28223 3/20 0.35
HTR2C P28335 3/20 0.35
KCNH2 Q12809 3/20 0.35
DRD2 P14416 2/20 0.35
LDHA P00338 2/20 0.34
LDHB P07195 2/20 0.34
NAMPT P43490 2/20 0.33
DNM1L O00429 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
ALDH1A1 P00352 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HDAC1 Q13547 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011396 0.93 CACNA1G (0.35) SMN1; SMN2RAB9ANPC1CACNA1GCACNA1H
SCHEMBL3014406 0.92 HTR2A (0.42) SMN1; SMN2RAB9ANPC1CACNA1GCACNA1H
SCHEMBL3010530 0.92 HTR2A (0.35) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL3022500 0.92 HTR2A (0.37) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL3017566 0.91 HTR2A (0.43) SMN1; SMN2RAB9ANPC1CACNA1GCACNA1H
SCHEMBL3012637 0.91 GBA1 (0.40) SMN1; SMN2RAB9ANPC1KMT2ACACNA1G
SCHEMBL3021350 0.90 RAB9A (0.34) SMN1; SMN2RAB9ANPC1CACNA1GCACNA1H
SCHEMBL3016374 0.89 SMN1; SMN2 (0.37) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL3011752 0.89 CACNA1G (0.38) SMN1; SMN2RAB9ANPC1CACNA1GCACNA1H
SCHEMBL3002715 0.88 MEN1 (0.39) SMN1; SMN2RAB9ANPC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885RAB9A 2943/4885NPC1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.